Status:
COMPLETED
Trial of NovoSeven® in Haemophilia - Joint Bleeds
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Eligibility:
MALE
Up to 20 years
Phase:
PHASE4
Brief Summary
This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively
Exclusion
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00108797
Start Date
September 1 2001
End Date
February 1 2006
Last Update
January 12 2017
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States, 72202
2
Novo Nordisk Investigational Site
Berkeley, California, United States, 94704
3
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90027
4
Novo Nordisk Investigational Site
Aurora, Colorado, United States, 80010